STAT55m
Lawmakers call for curbs on UnitedHealth’s growing empire
U.S. senators and other lawmakers argue the problems created by UnitedHealth's size and reach demand steps to restore public ...
STAT1h
Health Care’s Colossus: Inside STAT’s investigation of UnitedHealth
The killing of UnitedHealthcare CEO Brian Thompson has sparked extraordinary public interest in the nation’s health insurance ...
STAT7h
A tough year for health insurance stocks as patients get more care
This is the online version of STAT’s email newsletter Health Care Inc, delivered to your inbox every Monday. Sign up here. ...
STAT8h
Health care’s colossus, bird flu, and gender-affirming surgery
Today's health news includes the future of gender-affirming surgery, Democrats want to break up UnitedHealth, and more.
STAT13h
The recommended women’s health screening that rarely happens
Nearly every global society governing women’s health recommends screening adult women for incontinence. It seldom happens.
STAT13h
Gender-affirming surgery disappeared from the U.S. for decades. Now the field is fighting to keep its gains
One of those experts was Stanley Biber, a pioneer of vaginoplasties in the U.S. and perhaps the country’s busiest ...
STAT2d
Republicans dropped measures to help kids with cancer from the spending bill. Democrats pounced.
Shortly before the government-funding bill passed, Republican strategist Doug Heye said there simply wasn’t enough time to ...
STAT2d
Congress passes slimmed-down spending bill to keep government open
House lawmakers voted 366-34 to pass a spending bill on Friday. The Senate passed it on a 85-11 vote. The bill, which funds ...
STAT2d
In defense of state physician health programs’ work with medical students
To encourage robust, good-faith discussion about issues raised in First Opinion essays, STAT publishes selected Letters to ...
STAT3d
Eli Lilly’s obesity drug Zepbound approved to treat sleep apnea in U.S.
The FDA has cleared Eli Lilly’s obesity drug Zepbound as the first treatment for obstructive sleep apnea in the U.S.
STAT3d
What Novo Nordisk’s disappointing trial results mean for the obesity drug market
New clinical trial data from Novo Nordisk raise questions for the broad landscape of obesity drug development and the way ...
STAT3d
Next-gen obesity treatment from Novo Nordisk misses mark in pivotal trial
The treatment, called CagriSema, led patients to lose 20% of their weight at 68 weeks in a late-stage study when looking at ...